Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Indiana

Peptide legality · Indiana · updated 2026-09-21

Are peptides legal in Indiana?

Gray area

Indiana treats peptides as a gray-zone matter: it enacts no blanket ban and follows the federal compounding floor, so FDA-approved peptide drugs are legal by prescription while compounded and research peptides depend on unsettled federal rules and active litigation.

Legal status overview

Indiana is a gray-zone state, neither banning peptides outright nor clearing compounded or research peptides beyond what federal law permits. The Indiana Board of Pharmacy and Medical Licensing Board oversee the pharmacies and prescribers, but the core eligibility question is fixed federally under Sections 503A and 503B, and the GLP-1 compounding fight is playing out in statehouses and courthouses. FDA-approved peptide medicines and brand GLP-1 drugs such as Wegovy® (semaglutide) are legal to prescribe, including through Indiana telehealth. Compounded semaglutide remains accessible only with a documented patient-specific clinical reason, and research peptides such as BPC-157 stay unapproved and in regulatory limbo.

Key points

  • The fight over GLP-1 compounding is actively playing out in Indiana statehouses and courthouses, underscoring that peptide access in the state is contested rather than settled. [1]
  • Indiana does not set its own substantive list of compoundable substances; the eligibility baseline is fixed federally under Sections 503A and 503B, so peptide legality in Indiana tracks the national floor. [2]
  • Compounded semaglutide can still be accessed in Indiana, but after the post-shortage rules a licensed provider must document a patient-specific clinical reason or route the prescription through a licensed 503A compounding pharmacy. [5]
  • Indiana permits licensed providers to prescribe medicines, including GLP-1 drugs for weight management, following a telehealth consultation without a prior in-person visit. [5]
  • After the FDA declared the semaglutide shortage resolved, the shortage exception ended, so compounding a copy now requires a patient-specific clinical basis rather than cost or convenience. [6]
  • BPC-157 was removed from FDA Category 2 in April 2026 but not moved to Category 1, and with no FDA approval and no recognized monograph it remains in a regulatory gray zone. [3]
  • The FDA's Pharmacy Compounding Advisory Committee took up several peptides in July 2026 to consider inclusion on the 503A bulks list, but a recommendation is not the same as final approval, so eligibility stays pending. [4]
  • Compounded peptide preparations in Indiana are not FDA-approved; they are not a generic; and they have not been evaluated by the FDA for safety or effectiveness. [3]

Compound-by-compound status

BPC-157
Gray area
Removed from FDA Category 2 in April 2026 and reviewed by the Pharmacy Compounding Advisory Committee in July 2026 but not yet on Category 1; not FDA-approved, not a generic, not evaluated by the FDA, and not clearly eligible for lawful compounding in Indiana pending final rulemaking.
GLP-1 class (semaglutide, tirzepatide)
Gray area
Brand products such as Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound® (tirzepatide) are legal by prescription; compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and now requires a documented patient-specific clinical reason after the shortage ended.
TB-500 (thymosin beta-4)
Gray area
No FDA-approved drug product and no recognized compounding monograph; not FDA-approved, not a generic, not evaluated by the FDA, and available in Indiana only as a research chemical, not a medicine.
Growth hormone / somatropin
Restricted
FDA-approved somatropin products are legal by prescription for approved indications; federal law separately restricts growth hormone distribution for non-approved uses, so off-label or non-prescription distribution is unlawful.

Frequently asked questions

Are peptides legal in Indiana?

It depends on the peptide. FDA-approved peptide medicines are legal with a valid prescription from an Indiana-licensed prescriber. Compounded peptides depend on federal compounding rules that are being contested in court and the statehouse, and research-only peptides such as BPC-157 are not approved as medicines. This is general information, not medical or legal advice.

Is compounded semaglutide available in Indiana?

It can be accessed through a licensed 503A compounding pharmacy, but after the shortage ended a provider must document a patient-specific clinical reason. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA.

Can I get a GLP-1 prescription by telehealth in Indiana?

Yes. Indiana permits a licensed provider to prescribe medicines, including GLP-1 drugs for weight management, after a telehealth consultation, without requiring a prior in-person visit.

Who regulates peptide compounding in Indiana?

The Indiana Board of Pharmacy and the Medical Licensing Board of Indiana oversee the pharmacies and prescribers, while the FDA and Sections 503A and 503B of the federal Food, Drug, and Cosmetic Act set the underlying eligibility rules the state follows.

Is BPC-157 legal in Indiana?

BPC-157 is not FDA-approved. It was removed from FDA Category 2 in April 2026 and reviewed by the advisory committee in July 2026 but not yet added to the compounding bulks list, so it remains in regulatory limbo and is not clearly lawful to compound or dispense as a medicine in Indiana.

General information based on the sourced research above, not legal advice. For a specific situation in Indiana, consult a licensed attorney familiar with pharmaceutical law.